Evidence map›Paper›PMID 28083679›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2017

The effects of pleiotrophin in proliferative vitreoretinopathy.

Xue Ding, Yujing Bai, Xuemei Zhu, Tianqi Li, Enzhong Jin, Lvzhen Huang, Wenzhen Yu, Mingwei Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Xue DingDepartment of Ophthalmology, Peking University People's Hospital, Beijing, 100044, China.
Yujing BaiDepartment of Ophthalmology, Peking University People's Hospital, Beijing, 100044, China.
Xuemei ZhuDepartment of Ophthalmology, Peking University People's Hospital, Beijing, 100044, China.
Tianqi LiDepartment of Ophthalmology, Peking University People's Hospital, Beijing, 100044, China.
Enzhong JinDepartment of Ophthalmology, Peking University People's Hospital, Beijing, 100044, China.
Lvzhen HuangDepartment of Ophthalmology, Peking University People's Hospital, Beijing, 100044, China.
Wenzhen YuDepartment of Ophthalmology, Peking University People's Hospital, Beijing, 100044, China.
Mingwei ZhaoDepartment of Ophthalmology, Peking University People's Hospital, Beijing, 100044, China. zhaomingwei64@126.com.
Ministry of Education of the People's Republic of China · CNPeking University · CNPeking University People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of our study was to investigate the effects of pleiotrophin (PTN) in proliferative vitreoretinopathy (PVR) both in vitro and in vivo.

methodsImmunofluorescence was used to observe the PTN expression in periretinal membrane samples from patients with PVR and controls. ARPE-19 cells were exposed to TGF-β1. The epithelial-to-mesenchymal transition (EMT) of the ARPE-19 cells was confirmed by observed morphological changes and the increased expression of α-SMA and fibronectin at both the mRNA and protein levels. We used specific small interfering (si)RNA to knock down the expression of PTN. The subsequent effects of PTN inhibition were assessed with regard to the EMT, migration, proliferation, cytoskeletal arrangement, TGF-β signaling, PTN signaling, integral tight junction protein expression (e.g., claudin-1 and occludin), and p38 MAPK and p-p38 MAPK levels. Additionally, a PVR rat model was established by the intravitreal injection of ARPE-19 cells transfected with PTN-siRNA and was evaluated accordingly.

resultsPTN was highly expressed in PVR membranes compared to controls. PTN knockdown attenuated the TGF-β1-induced migration, proliferation, cytoskeletal rearrangement, and expression of EMT markers such as α-SMA and fibronectin in the ARPE-19 cells, and these effects may have been mediated through p38 MAPK signaling pathway activation. PTN silencing inhibited the up-regulation of claudin-1 and occludin stimulated by TGF-β1, and PTN knockdown inhibited the proliferative aspects of severe PVR in vivo.

conclusionsPTN is involved in the process of EMT induced by TGF-β1 in human ARPE-19 cells in vitro, and PTN knockdown attenuated the progression of experimental PVR in vivo. These findings provide new insights into the pathogenesis of PVR.

Indexed as

Gene Expression RegulationAnimalsBlotting, WesternCarrier ProteinsCell MovementCell ProliferationCells, CulturedCytokinesDisease Models, AnimalEpithelial-Mesenchymal TransitionHumansImmunohistochemistryMicroscopy, FluorescenceRatsReal-Time Polymerase Chain ReactionRetrospective StudiesCarrier ProteinsCytokinespleiotrophinRNA, MessengerEpithelial-to-mesenchymal transition (EMT)Pleiotrophin (PTN)Proliferative vitreoretinopathy (PVR)siRNATGF-β

Identifiers

PMID28083679
OpenAlexW2575715265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.